Bundle (CJC1295 (DAC) 2mg x5 + Ipamorelin 2mg x5)

This bundle pairs five individually-supplied vials of CJC-1295 with DAC (2mg) with five individually-supplied vials of Ipamorelin (2mg), covering both major receptor pathways studied in growth hormone secretagogue research without committing to a fixed mixing ratio.

Two Receptor Pathways, Supplied Separately

CJC-1295 with DAC engages the GHRH receptor, while Ipamorelin engages the growth hormone secretagogue receptor (GHS-R), a distinct pathway activated naturally by ghrelin.

Because each vial in this bundle contains a single peptide rather than a co-formulated blend, each is independently verified against its own specification, distinct from a pre-mixed formulation where the two peptides would be combined at a single, fixed ratio determined during manufacturing.

GHRH Receptor Engagement

Structural and computational research has characterized the dynamic properties of the GHRH receptor and the molecular determinants of GHRH binding, providing a receptor-level basis for how CJC-1295's retained GHRH-derived sequence is understood to engage this receptor.¹

The DAC modification itself, a maleimidopropionyl-lysine extension that reacts with a free cysteine thiol on serum albumin via maleimide chemistry, is a structural addition separate from the GHRH-receptor-binding region, leaving the underlying GHRH-receptor interaction unchanged from the unconjugated analog.

GHS-R Selectivity Considerations

A recurring theme in secretagogue research is the degree to which a given peptide activates GHS-R without cross-activating adjacent pituitary pathways governing hormones such as ACTH or cortisol.

Ipamorelin is frequently cited in laboratory literature as a comparatively selective GHS-R ligand within this research framework, a property attributed to its specific structural features, including an Aib residue that restricts backbone rotation relative to standard amino acids.

Combined Research Applications

Because these two peptides engage separate receptor pathways, this bundle supports research examining potential convergence between GHRH-receptor and GHS-R signaling within the same experimental platform.

The specific consequences of pairing GHRH-receptor and GHS-R signaling in the same experimental platform remain an open question in laboratory research, with available data on such combinations still preliminary.

Verifying Ten Vials Across Two Compounds

A bundle spanning two different peptides across ten total vials means purity data for one compound says nothing about the other, so each peptide's certificate of analysis needs to be checked on its own terms rather than assumed from the bundle's overall specification.

For the DAC-conjugated peptide specifically, this extends to mass-spectrometric confirmation that the maleimide group remains intact, since a hydrolyzed maleimide would compromise albumin-binding capacity without necessarily changing overall peptide mass.

Storage and Handling in the Laboratory Setting

Both peptides are best kept lyophilized under sub-zero freezer conditions until shortly before use.

CJC-1295 with DAC additionally requires moisture-limited packaging, since its reactive maleimide group is more sensitive to ambient humidity than the peptide backbone itself, an added consideration not shared by Ipamorelin.

Important Notice

CJC-1295 with DAC and Ipamorelin are strictly for in vitro laboratory research purposes only and are not intended for human consumption. These findings do not establish safety, efficacy, or suitability for any human application, and these products have not been evaluated by the FDA or any regulatory agency.

Product Information

This bundle includes 5 vials of CJC-1295 with DAC at 2mg per vial and 5 vials of Ipamorelin at 2mg per vial, supplied as lyophilized powders for laboratory research use only.

References

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.